sur INVENTIVA (EPA:IVA)
Inventiva Announces Preliminary Financial Results for 2024
Inventiva has released its preliminary financial results for the year 2024. Revenues amounted to €9.2 million, while cash reached €96.6 million as of December 31, 2024. The company raised a first tranche of structured financing totaling €116 million.
In terms of research, the last patient for Phase 3 of the NATiV3 study on lanifibranor was screened in early 2025. The company has decided to reorient its strategy, focusing exclusively on the development of lanifibranor and reducing staff by 50%.
R&D expenses decreased by 17% in 2024, reaching €90.9 million, mainly due to the pause in patient recruitment for the NATiV3 study. A restart of these activities is planned in 2025.
R. P.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de INVENTIVA